Clinical trial
Prospective Phase ii Clinical Study of the Efficacy and Safety of Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment With Platinum-containing Chemotherapy in Extensive Stage Small Cell Lung Cancer With Oligometastases (1-5 Lesions)
NCT05484583 is registered in ClinicalTrials.gov with Affiliated Cancer Hospital & Institute of Guangzhou Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Phase ii Clinical Study of the Efficacy and Safety of Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment With Platinum-containing Chemotherapy in Extensive Stage Small Cell Lung Cancer With Oligometastases (1-5 Lesions)
- Lead sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- August 1, 2022
- Completion date
- August 1, 2027
- Enrollment
- 58 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
extensive-stage small-cell lung cancer, lung cancer, radiotherapy